Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Oasis Ultra in Diabetic Foot Ulcers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Healthpoint
ClinicalTrials.gov Identifier:
NCT01835379
First received: April 16, 2013
Last updated: September 25, 2014
Last verified: September 2014
  Purpose

Many people with diabetes will develop a non-healing diabetic foot ulcer. Many ways are available to try to get a diabetic foot ulcer to heal, including application of Oasis Ultra. The hypothesis to be tested is that application of Oasis Ultra will cause more diabetic foot ulcers to heal than wounds treated with regular medical care. Subjects will have their diabetic foot wounds treated for up to 12 weeks with Oasis Ultra or regular medical care .


Condition Intervention Phase
Diabetic Foot Ulcer
Device: Oasis
Other: Standard
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open Label Controlled Trial of OASIS® Ultra Tri-Layer Matrix Compared to Standard Care in the Healing of Diabetic Foot Ulcers

Resource links provided by NLM:


Further study details as provided by Healthpoint:

Primary Outcome Measures:
  • Proportion of Wounds Closed [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Days to Wound Closure [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]

Enrollment: 82
Study Start Date: May 2013
Study Completion Date: September 2014
Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oasis
Oasis
Device: Oasis
Oasis Ultra will be applied once per week for up to 12 weeks.
Standard
Standard Care
Other: Standard
Other Name: Standard Care

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
  • Subjects 18 years of age or older of either sex with a history of diabetes mellitus (Type 1 or 2) requiring medication (insulin and/or oral/injectable) to control blood glucose levels.
  • A non-healing, Wagner grade 1 or 2, neuropathic diabetic foot ulcer.
  • Willing and able to make all required study visits.
  • Able to follow instructions.
  • An ulcer present on any part of the plantar surface of the foot, which is 0.5 cm2 to 10 cm2 (inclusive), as measured at the Screening Visit prior to debridement, with a duration ≥ 6 weeks (documented in the patient's history or by patient report of onset) but not more than 12 months.
  • Separation of at least 5 cm (wound edge to wound edge) if ≥ 2 wounds are present.
  • Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.7 and ≤ 1.1. If the ABI is greater than 1.1, then a toe pressure of > 40 mmHg OR a transcutaneous oxygen pressure (TcPO2) ≥ 40 mmHg must be present. Either toe pressure or TcPO2 is also acceptable in lieu of ABI, but if both are obtained, each must meet its respective cutoff.

Alternatively, a Doppler waveform consistent with adequate flow to the region of the foot with the target ulcer (biphasic or triphasic waveforms) is acceptable (test result must be included in the source document).

  • Target ulcer is not infected based on clinical assessment.
  • Able to perform any required dressing changes at home or have a caregiver who can perform the dressing changes.
  • Willing to use an appropriate off-loading device to keep weight off of foot ulcers.
  • Blood counts and blood chemistry values as follows:

    • Alanine aminotransferase (ALT) ≤ 3x upper limit of normal
    • Aspartate aminotransferase (AST) ≤ 3x upper limit of normal
    • Serum albumin ≥ 2.0 g/dL •Pre-albumin levels of ≥ 10 mg/dL
    • Alkaline phosphatase ≤ 500 U/L •Serum total bilirubin ≤ 3.0 mg/dL
    • Serum BUN < 75 mg/dL •Serum creatinine ≤ 4.5 mg/dL
    • HbA1c ≤ 12% •Hemoglobin (Hgb) > 8.0 g/dL
    • WBC > 2.0 x 109/L •Absolute neutrophil count > 1.0 x 109/L
    • Platelet count > 50 x 109/L

Exclusion Criteria:

  • Contraindications or hypersensitivity to the use of the study device or its components (e.g., porcine sensitivity).
  • Participation in another investigational study within thirty (30) days of Visit 1 or planned participation overlapping with this study.
  • Subjects with evidence of gangrene on either lower limb.
  • Ulcers that require negative pressure or hyperbaric oxygen therapy.
  • The Medical Monitor may declare any subject ineligible for a valid medical reason.
  • Current treatment with disallowed medications or therapies. Subjects may not be enrolled into the study while using systemic antibiotics.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01835379

Locations
United States, Arkansas
Little Rock, Arkansas, United States, 72205
United States, California
Carlsbad, California, United States, 92009
Fair Oaks, California, United States, 95628
Fresno, California, United States, 93720
San Diego, California, United States, 92103
United States, Indiana
Evansville, Indiana, United States, 47713
United States, Kentucky
Madisonville, Kentucky, United States, 42431
United States, Louisiana
Shreveport, Louisiana, United States, 71101
United States, Michigan
Saginaw, Michigan, United States, 48602
United States, New Jersey
Bayonne, New Jersey, United States, 07002
United States, Texas
Dallas, Texas, United States, 75243
Dallas, Texas, United States, 75224
Fort Worth, Texas, United States, 76104
Houston, Texas, United States, 77036
McAllen, Texas, United States, 78501
United States, Virginia
Virginia Beach, Virginia, United States, 23464
Sponsors and Collaborators
Healthpoint
Investigators
Study Chair: Herbert B Slade, MD Healthpoint
  More Information

No publications provided

Responsible Party: Healthpoint
ClinicalTrials.gov Identifier: NCT01835379     History of Changes
Other Study ID Numbers: 815-999-09-010
Study First Received: April 16, 2013
Last Updated: September 25, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Healthpoint:
Diabetes
Diabetic Foot Ulcer
Diabetic Foot Wound
Non-healing foot wound
Oasis
Diabetic neuropathy

Additional relevant MeSH terms:
Diabetic Foot
Foot Ulcer
Ulcer
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Diabetic Angiopathies
Diabetic Neuropathies
Endocrine System Diseases
Foot Diseases
Leg Ulcer
Pathologic Processes
Skin Diseases
Skin Ulcer
Vascular Diseases

ClinicalTrials.gov processed this record on November 19, 2014